UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization

Neurology, 2010-01, Vol.74 (3), p.201-209

2010

Volltextzugriff (PDF)

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

Neurology, 2011-08, Vol.77 (6), p.556-563

2011

Volltextzugriff (PDF)

APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study

Molecular psychiatry, 2014-03, Vol.19 (3), p.351-357

2014

Volltextzugriff (PDF)

Comparing predictors of conversion and decline in mild cognitive impairment

Neurology, 2010-07, Vol.75 (3), p.230-238

2010

Volltextzugriff (PDF)

A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease

Neurology, 2006-11, Vol.67 (10), p.1757-1763

2006

Volltextzugriff (PDF)

Chronic divalproex sodium use and brain atrophy in Alzheimer disease

Neurology, 2011-09, Vol.77 (13), p.1263-1271

2011

Volltextzugriff (PDF)

Serial MRI and CSF biomarkers in normal aging, MCI, and AD

Neurology, 2010-07, Vol.75 (2), p.143-151

2010

Volltextzugriff (PDF)

Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment

Neurology, 2008-01, Vol.70 (3), p.191-199

2008

Volltextzugriff (PDF)

Randomized pilot study of nimesulide treatment in Alzheimer's disease

Neurology, 2002-04, Vol.58 (7), p.1050-1054

2002

Volltextzugriff (PDF)

Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects

Neurology, 2010-11, Vol.75 (22), p.1976

2010

Volltextzugriff (PDF)

Effect of tramiprosate in patients with mild-to-moderate alzheimer’s disease: Exploratory analyses of the MRI sub-group of the alphase study

The Journal of nutrition, health & aging, 2009-06, Vol.13 (6), p.550-557

2009

Volltextzugriff (PDF)

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease

Brain (London, England : 1878), 2010-11, Vol.133 (11), p.3336-3348

2010

Volltextzugriff (PDF)

A phase II trial of huperzine A in mild to moderate Alzheimer disease

Neurology, 2011-04, Vol.76 (16), p.1389-1394

2011

Volltextzugriff (PDF)

Defining the Optimal Target Population for Trials of Polyunsaturated Fatty Acid Supplementation Using the Erythrocyte Omega-3 Index: A Step Towards Personalized Prevention of Cognitive Decline?

The Journal of nutrition, health & aging, 2018-10, Vol.22 (8), p.982-988

2018

Volltextzugriff (PDF)

Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials

The Journal of Prevention of Alzheimer's Disease, 2020, Vol.7 (4), p.213-218

2020

Volltextzugriff (PDF)

FASTKD2 is associated with memory and hippocampal structure in older adults

Molecular psychiatry, 2015-10, Vol.20 (10), p.1197-1204

2015

Volltextzugriff (PDF)

Characterizing Clinical Progression in Cognitively Unimpaired Older Individuals with Brain Amyloid: Results from the A4 Study

The Journal of Prevention of Alzheimer's Disease, 2024, Vol.11 (4), p.814-822

2024

Volltextzugriff (PDF)

Estimating Socio-Economic Status for Alzheimer’s Disease Trials

The Journal of Prevention of Alzheimer's Disease, 2024, Vol.11 (5), p.1418-1425

2024

Volltextzugriff (PDF)

Change in Digital Cognitive Test Performance between Solanezumab and Placebo Groups in Preclinical Alzheimer’s Disease: Secondary Analyses from the A4 Study

The Journal of Prevention of Alzheimer's Disease, 2024, Vol.11 (4), p.846-856

2024

Volltextzugriff (PDF)

Longitudinal Trajectories of the Cognitive Function Index in the A4 Study

The Journal of Prevention of Alzheimer's Disease, 2024, Vol.11 (4), p.838-845

2024

Volltextzugriff (PDF)

Safety Profile of a Cognitively Unimpaired Older Population with Elevated Cerebral Amyloid in a 4.5-Year Clinical Trial

The Journal of Prevention of Alzheimer's Disease, 2024, Vol.11 (4), p.857-868

2024

Volltextzugriff (PDF)

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

JAMA : the journal of the American Medical Association, 2003-06, Vol.289 (21), p.2819

2003

Volltextzugriff (PDF)

Maximizing the Utility of Alzheimer’s Disease Trial Data: Sharing of Baseline A4 and LEARN Data

The Journal of Prevention of Alzheimer's Disease, 2024, Vol.11 (4), p.889-894

2024

Volltextzugriff (PDF)

Sensitivity of the Preclinical Alzheimer’s Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer’s Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial

The Journal Of Prevention of Alzheimer's Disease, 2022, Vol.9 (2), p.255-261

2022

Volltextzugriff (PDF)

Pre-Randomization Predictors of Study Discontinuation in a Preclinical Alzheimer’s Disease Randomized Controlled Trial

The Journal of Prevention of Alzheimer's Disease, 2024, Vol.11 (4), p.874-880

2024

Volltextzugriff (PDF)

1 – 25 von 204

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(188)
Mit Volltextzugriff
(131)

Publikationsform

Artikel
(204)

Sprache

Englisch
(203)
Portugiesisch
(1)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study

Comparing predictors of conversion and decline in mild cognitive impairment

A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease

Chronic divalproex sodium use and brain atrophy in Alzheimer disease

Serial MRI and CSF biomarkers in normal aging, MCI, and AD

Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment

Randomized pilot study of nimesulide treatment in Alzheimer's disease

Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects

Effect of tramiprosate in patients with mild-to-moderate alzheimer’s disease: Exploratory analyses of the MRI sub-group of the alphase study

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease

A phase II trial of huperzine A in mild to moderate Alzheimer disease

Defining the Optimal Target Population for Trials of Polyunsaturated Fatty Acid Supplementation Using the Erythrocyte Omega-3 Index: A Step Towards Personalized Prevention of Cognitive Decline?

Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials

FASTKD2 is associated with memory and hippocampal structure in older adults

Characterizing Clinical Progression in Cognitively Unimpaired Older Individuals with Brain Amyloid: Results from the A4 Study

Estimating Socio-Economic Status for Alzheimer’s Disease Trials

Change in Digital Cognitive Test Performance between Solanezumab and Placebo Groups in Preclinical Alzheimer’s Disease: Secondary Analyses from the A4 Study

Longitudinal Trajectories of the Cognitive Function Index in the A4 Study

Safety Profile of a Cognitively Unimpaired Older Population with Elevated Cerebral Amyloid in a 4.5-Year Clinical Trial

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

Maximizing the Utility of Alzheimer’s Disease Trial Data: Sharing of Baseline A4 and LEARN Data

Sensitivity of the Preclinical Alzheimer’s Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer’s Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial

Pre-Randomization Predictors of Study Discontinuation in a Preclinical Alzheimer’s Disease Randomized Controlled Trial

Aktive Filter

Suchergebnisse filtern